Company Insights

BCAX supplier relationships

Explore interactive graphBrowse insights index
BCAX supplier relationship map

BCAX (Bicara Therapeutics) — supplier relationships and what investors need to know

Bicara Therapeutics is a clinical‑stage biopharmaceutical company that develops bifunctional fusion proteins for solid tumors. It monetizes by advancing clinical candidates to regulatory milestones and commercial readiness through a combination of in‑licensing, outsourced manufacturing and development services, and recurring capital markets activity to fund operations; ultimate revenue will come from product sales and potential partnering/licensing arrangements once programs are approved. For investors and operators the critical lens is supply‑chain concentration, contractual structure and the financial plumbing that supports runways and scale. Learn more at https://nullexposure.com/.

Quick read: the supplier and capital markets map in one line

Bicara outsources virtually all drug substance and product manufacturing to contract manufacturers and contract research organizations while using major investment banks and brokers to raise equity capital and registered service providers for audit, counsel and transfer agent duties. That combination creates concentrated operational risk tied to a small group of CMOs and predictable financial dependencies on capital markets.

Supplier and partner roster — plain English summaries

Below are every relationship referenced in the sourced materials, each with a concise description and a source reference.

  • Biocon Biologics, Ltd. — Identified in the FY2024 Form 10‑K as one of Bicara’s principal clinical drug suppliers; Biocon also provided broader services under a master services agreement. Source: Bicara FY2024 10‑K filings (FY2024).

  • Biocon Biologics Limited (BBL) — Bicara executed multiple BBL agreements (manufacturing, quality, material transfer and services) across 2023–2024 to support R&D and manufacturing purchase orders. Source: Bicara FY2024 10‑K (BBL Agreements, December 2023 and earlier).

  • Syngene / Syngene International Limited — Syngene is a wholly‑owned Biocon subsidiary that Bicara contracted in 2019 (manufacturing and master contract services); Syngene supplies specified quantities for R&D and performs contract research services under those agreements. Source: Bicara FY2024 10‑K (Syngene Agreements, 2019–2020).

  • WuXi Biologics (Hong Kong) Limited / WuXi Bio — Bicara states it “primarily relies on one manufacturer, WuXi Biologics…for the production of product necessary to complete our ongoing clinical trials,” placing WuXi at the center of clinical supply. Source: Bicara FY2024 10‑K (FY2024).

  • Thermo Fisher Scientific — Named as a provider of drug product and packaging services and affiliated entities are listed among product/packaging suppliers. Source: Bicara FY2024 10‑K (FY2024).

  • IQVIA RDS Inc. (IQVIA) — Bicara has a master clinical contract services agreement (entered October 2019, amended December 2023) under which IQVIA supplies global clinical‑development and laboratory services; Bicara reported material spend to IQVIA in 2023–2024. Source: Bicara FY2024 10‑K (Master clinical services agreement, 2019; amended 2023).

  • Biocon Limited — Bicara entered a Contract Transfer and License Agreement with Biocon Limited on October 1, 2019, under which Biocon licensed rights related to fusion protein products and granted sublicensing rights. Source: Bicara FY2024 10‑K (Biocon Agreement, Oct 2019).

  • Morgan Stanley & Co. LLC / Morgan Stanley — Acted as a joint book‑running manager on the February 2026 public offering; Morgan Stanley is listed in the prospectus supplement as a lead underwriter and purchaser of shares and pre‑funded warrants. Source: Prospectus supplement and news releases (Feb–Mar 2026).

  • BofA Securities, Inc. / BofA Securities — Served as a joint book‑running manager in the 2026 equity offering and is listed among underwriters purchasing shares and warrants. Source: Prospectus supplement and press release (Feb 2026).

  • Cantor Fitzgerald & Co. / Cantor — Listed as a joint book‑running manager in the 2026 offering and shown as allocated shares and pre‑funded warrants in the prospectus supplement. Source: Prospectus supplement and news coverage (Feb–Mar 2026).

  • Stifel, Nicolaus & Company, Incorporated / Stifel — Participated as a joint book‑running manager for the February 2026 offering and is recorded as an underwriter in closing disclosures. Source: Press releases and offering documents (Feb 2026).

  • TD Cowen / TD Cowen (COWN) — Named as a joint book‑running manager in the 2026 offering and identified in press coverage of the transaction; TD Cowen also appears as sales agent relations for equity program mentions in public notices. Source: Press releases and news coverage (Feb–Mar 2026).

  • TD Securities (USA) LLC — Identified in the prospectus supplement as the sales agent for Bicara’s at‑the‑market offering program under a Sales Agreement dated October 3, 2025. Source: Prospectus supplement (FY2026).

  • KPMG LLP — Independent registered public accounting firm; Bicara incorporated its consolidated financial statements by reference in the prospectus supplement relying on KPMG’s audit report. Source: Prospectus supplement (FY2026).

  • Goodwin Procter LLP — Served as Bicara’s legal counsel for the offering; Goodwin passed on the validity of the shares and pre‑funded warrants in the offering documents. Source: Prospectus supplement (FY2026).

  • Computershare Trust Company, N.A. — Serves as the transfer agent and registrar for Bicara common stock per the prospectus supplement. Source: Prospectus supplement (FY2026).

  • UBS Financial Services Inc. / UBS Financial Services, Inc. — Named as broker in filings documenting exercises of stock options and related sales transactions in March 2026. Source: SEC filing disclosures (March 2026).

  • Others listed generically (Cantor / Cantor Fitzgerald variants) — Multiple press outlets and the prospectus record Cantor/Fitzgerald variants as underwriters or participants in the offering; their role is underwriting and distribution. Source: Press releases and offering documents (Feb–Mar 2026).

What the constraints tell investors about operating risk and contracting posture

The company filings and constraint excerpts collectively define a clear operating model signal:

  • Outsourced and license‑heavy model. Bicara relies on intellectual property licenses (the Biocon Agreement) for its core product rights and uses third‑party CMOs and CROs to execute R&D, manufacturing and clinical programs. This is a structural characteristic of the company’s go‑to‑market model and capital intensity. Source: FY2024 10‑K (licensing and Biocon Agreement).

  • Concentration risk is material. Management explicitly identifies reliance on one primary manufacturer (WuXi Bio) for the production needed to complete ongoing clinical trials and names Biocon/Biocon Biologics and Syngene as principal clinical suppliers; that creates a single‑point manufacturing exposure for trial continuity. Source: FY2024 10‑K (manufacturer dependency excerpts).

  • Contracting posture blends licensing, manufacturing and services. Public excerpts show active license agreements (Biocon), manufacturing agreements (Syngene, BBL, WuXi), and master services agreements for clinical work (IQVIA and Biocon master services), indicating multi‑tiered outsourcing rather than captive production. Source: FY2024 10‑K (contract excerpts).

  • Relationships are active and operationally critical. Spend disclosures and active amendments through 2023–2024 show these relationships are currently operational and material to ongoing trials, not legacy or dormant contracts. Source: FY2024 10‑K (expense and payment figures; active contract dates).

  • Geographic footprint aligns with North American trials but global supply. Bicara conducts trials in the U.S. and Canada but sources manufacturing through global CMOs, reflecting a cross‑border supply chain. This is a company‑level signal from the filings. Source: FY2024 10‑K (clinical geography statements).

Investment implications and recommended next steps

  • Key risk: manufacturing concentration. The single‑provider reliance for clinical supply is the principal operational vulnerability investors must price. Mitigation steps for operators include accelerated dual‑sourcing, inventory buffering of clinical lots, or explicit contingency contracting with alternate CMOs.

  • Capital markets are a core financing channel. The February 2026 $150m public offering underwritten by a stable syndicate (Morgan Stanley, BofA, TD Cowen, Cantor, Stifel) demonstrates ready access to equity markets but also dependence on periodic dilutive raises. Source: Prospectus supplement and press releases (Feb–Mar 2026).

  • Governance and service backbone are in place. KPMG as auditor, Goodwin as counsel and Computershare as transfer agent reflect standard public‑company controls and service relationships that support liquidity and capital activity. Source: Prospectus supplement (FY2026).

If you want a concise risk matrix or a prioritized action plan to stress‑test Bicara’s supplier concentration and financing runway, start at the home page: https://nullexposure.com/. For a tailored supplier‑risk brief or to monitor changes to BCAX’s relationships in near real time, visit https://nullexposure.com/ for subscription options and analyst support.

Closing takeaway: Bicara’s model is capital intensive and outsourcing dependent, with a small set of manufacturers and service providers carrying operational criticality. Investors should treat supply‑chain concentration and ongoing access to capital as the two primary levers driving near‑term value and execution risk. Learn more at https://nullexposure.com/.